Clinical Trials Browser

Phase 2 × Myelodysplastic Syndromes × Darbepoetin alfa × Clear all

NCT01222195 2012-08-07

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Phase 2 Terminated

1 enrolled 5 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes